10,231 Shares in Stryker Corporation $SYK Bought by Madison Asset Management LLC

Madison Asset Management LLC bought a new position in shares of Stryker Corporation (NYSE:SYK - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 10,231 shares of the medical technology company's stock, valued at approximately $3,221,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Sankala Group LLC bought a new stake in shares of Stryker in the 4th quarter valued at about $26,000. Godfrey Financial Associates Inc. bought a new position in shares of Stryker during the fourth quarter worth about $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker during the third quarter worth about $27,000. Atlas Capital Advisors Inc. acquired a new position in shares of Stryker in the fourth quarter worth approximately $27,000. Finally, Gables Capital Management Inc. acquired a new position in shares of Stryker in the second quarter worth approximately $25,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company's stock, valued at $2,088,423. This trade represents a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 665,370 shares of company stock worth $216,238,501 in the last three months. Company insiders own 4.60% of the company's stock.

Stryker Stock Down 3.5%

Stryker stock opened at $327.97 on Friday. The company has a market capitalization of $125.80 billion, a PE ratio of 33.99, a PEG ratio of 2.17 and a beta of 0.76. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The firm's fifty day moving average is $326.64 and its 200 day moving average is $332.66. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. During the same period last year, the company posted $3.13 earnings per share. The business's quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Raymond James Financial set a $370.00 target price on shares of Stryker in a research report on Friday, July 31st. Barclays dropped their price target on shares of Stryker from $469.00 to $394.00 and set an "overweight" rating on the stock in a research report on Monday, May 4th. Evercore set a $350.00 price objective on shares of Stryker in a research note on Monday, July 6th. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research report on Friday, May 1st. Finally, Wall Street Zen raised shares of Stryker from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source